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JANGKITAN PADA KAWASAN TAPAK PEMBEDAHAN DALAM 
KALANGAN PESAKIT YANG MENJALANI PEMBEDAHAN BERSIH DAN 
PEMBEDAHAN BERSIH TERCEMAR DI HOSPITAL UNIVERSITI SAINS 
MALAYSIA: FAKTOR RISIKO, PROFIL Staphylococcus aureus DAN 
PROFIL MIKROBIOLOGI 
  
ABSTRAK 
Infeksi luka di tapak kawasan pembedahan (ILTKP) adalah diantara 
masalah kesihatan yang kerap dialami oleh pesakit yang menjalani pembedahan 
di hospital. Kejadian ini dipantau secara rutin kerana ia melibatkan peningkatan 
kadar mortaliti, morbiditi, dan juga kos rawatan. Jangkitan ini biasanya 
disebabkan oleh mikroorganisma seperti Staphylococcus aureus, Streptococcus 
spp, Enterococcus spp, dan Pseudomonas aeruginosa. Kenalpasti jenis 
mikroorganisma penyebab serta corak kepekaan antimikrobial amat membantu 
dalam pelan rawatan. Oleh itu, tujuan kajian ini adalah untuk menentukan kadar 
dan faktor risiko ILTKP serta mengenal pasti agen penyebab dan corak kepekaan 
antimikrobialnya. 
Prospektif kajian kohort ini dijalankan dari Jun 2013 hingga Julai 2014 di 
Hospital Universiti Sains Malaysia. Tujuh puluh dua orang pesakit yang menjalani 
pembedahan bersih dan bersih tercemar telah bersetuju untuk menyertai kajian 
ini dan mereka dipantau sama ada terdapat sebarang tanda-tanda ILTKP selama 
30 hari selepas pembedahan. Pemeriksaan calitan hidung untuk mengesan 
Staphylococcus aureus dan Methicillin-resistance Staphylococcus aureus juga 
telah dijalankan sebelum pembedahan. Sampel tisu atau swab luka telah diambil 
xvii 
 
dari luka pesakit yang dijangkiti untuk mengenal pasti mikroorganisma yang 
menyebabkan jangkitan serta corak kepekaan antimikrobialnya. Bagi 
mikroorganisma Staphylococcus aureus analisis molekular telah dijalankan untuk 
mengesan kewujudan gen virulen seperti TSST, PVL, cna, hlg, icaA, dan SdrE. 
Prevalen ILTKP untuk pembedahan bersih dan bersih tercemar adalah 
masing-masing 20% dan 11.8%. Analisis regresis logistik ringkas menunjukkan 
bahawa risiko berkaitan ILTKP ialah pesakit yang dimasukkan dua hari dan lebih 
sebelum pembedahan (OR 12.67; 95% CI, 2.02 to 79.53), menjalani 
pembedahan CABG (OR 10.20; 95% CI, 2.66 to 39.08), mempunyai penyakit 
yang tersirat (OR 9.46; 95% CI, 1.15 to 77.50), sejarah kencing manis sebelum 
pembedahan (OR 9.40; 95% CI, 2.36 to 37.39), jumlah tempoh dimasukkan ke 
hospital lebih daripada tujuh hari (OR 7.84; 95% CI, 2.12 to 29.0), tempoh 
pembedahan melebihi empat jam (OR 7.08; 95% CI, 1.84 to 27.27), dan keluar 
dari hospital tiga hari atau lebih selepas pembedahan (OR 5.13; 95% CI, 1.39 to 
18.84). 
Analisis regresis logistik berganda pula menunjukkan bahawa pesakit 
yang mempunyai sejarah kencing manis (OR 6.97; 95% CI, 1.49 to 32.71) dan 
pesakit yang menjalani pembedahan CABG (OR 5.54; 95% CI, 1.22 to 25.03) 
mempunyai risiko ILTKP yang tinggi. Gram negatif mikroorganisma adalah 
penyebab utama ILTKP. icaA gen adalah gen virulen yang paling biasa dikesan 
pada Staphylococcus aureus. 
Kesimpulannya, ILTKP pada pembedahan bersih dan bersih tercemar 
adalah tinggi di hospital USM. Pesakit yang menghidap kencing manis dan 
pesakit yang menjalani pembedahan CABG adalah berisiko tinggi untuk 
xviii 
 
mendapat ILTKP. Mikroorganisma Gram negatif adalah lebih kerap menjangkiti 
pesakit berbanding Gram positif dan semua mikroorganisma ini adalah dalam 
kumpulan yang peka kepada antibiotik. 
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SURGICAL SITE INFECTIONS AMONG PATIENTS UNDERWENT CLEAN 
AND CLEAN-CONTAMINATED SURGERY IN HOSPITAL UNIVERSITI SAINS 
MALAYSIA: RISK FACTORS, MICROBIOLOGICAL AND Staphylococcus 
aureus MOLECULAR PROFILE 
 
ABSTRACT 
Surgical site infections (SSI) are among the most commonly encountered 
healthcare associated infection. The incidence were closely been monitored as it 
is associated with considerable morbidity and mortality. The common aetiological 
agents responsible for the infection include Staphylococcus aureus, 
Streptococcus spp, Enterococcus spp, and Pseudomonas aeruginosa. The 
identification of the causative agents as well as their antimicrobial sensitivity 
pattern helps in the treatment plan. Therefore the aims of this study were to 
determine the incidence and risk factors of SSI as well as to identify the causative 
microorganisms and their sensitivity profile. 
This prospective cohort study was conducted from June 2013 until July 
2014 at Hospital Universiti Sains Malaysia. Seventy-two patients underwent 
clean and clean-contaminated surgeries were consented preoperatively and 
strictly followed up for any signs of SSI for duration of 30 days post operation. 
Nasal screening for Staphylococcus aureus and Methicillin-resistance 
Staphylococcus aureus was carried out preoperatively. Tissue samples or wound 
swab from infected patients were taken for microbial identification and its 
sensitivity pattern. Staphylococcus aureus strain isolated were proceed to 
xx 
 
polymerase chain reaction analysis to detect the virulence genes (TSST, PVL, 
cna, hlg, icaA, and SdrE). 
The overall incidence rate of SSI was 18.1% specifically for clean and 
clean-contaminated surgeries are 20% and 11.8%, respectively. Significant risk 
associated with SSI by simple logistic regression analysis included patients 
admitted two days or more prior to surgery (OR 12.67; 95% CI, 2.02 to 79.53), 
underwent CABG surgery (OR 10.20; 95% CI, 2.66 to 39.08), underlying 
diseases (OR 9.46; 95% CI, 1.15 to 77.50), history of diabetes mellitus (DM) prior 
to the surgery (OR 9.40; 95% CI, 2.36 to 37.39), total hospitalization period more 
than seven days (OR 7.84; 95% CI, 2.12 to 29.0), duration of surgery more than 
four hours (OR 7.08; 95% CI, 1.84 to 27.27), and discharged home three days or 
longer after surgery (OR 5.13; 95% CI, 1.39 to 18.84). 
Multiple logistic regression method demonstrated that the patients who 
have history of DM (OR 6.97; 95% CI, 1.49 to 32.71) and underwent CABG 
surgery (OR 5.54; 95% CI, 1.22 to 25.03) had significant risks of SSI. Gram 
negative microorganism was the leading causative microorganism and in 
Staphylococcus aureus strains, icaA gene was the most common virulence gene 
detected. 
In conclusion, SSI among clean and clean-contaminated surgeries are 
high in our setting. DM and patients underwent CABG operation are at high risk 
to get SSI. Gram negative microorganisms are common as compare to Gram 
positive, however they are all sensitive strains. 
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CHAPTER 1   
INTRODUCTION 
Surgery is one of the major and important branches of medicine that 
perform a surgical procedure to the human body for diagnostic, treatment, 
prevention as well as palliative purpose. Microorganisms have an opportunity to 
invade when a part of the body is operated during surgical procedure and causing 
a post-operative infection. Such infection occurred post-operatively and was 
referred as surgical site infection (SSI). 
The previous term ‘Surgical Wound Infection’ was replaced by the term 
‘SSI’ in year 1992 (Horan et al., 1992). SSI is defined as an infection that occurs 
at site of incision, or any anatomical parts that was either opened or manipulated 
during the procedure that occurs within 30 days after surgery, or within one year 
if involve implantation (Horan et al., 1992). However, based on the Centers for 
Disease Control and Prevention (CDC) criteria, stitch abscess was not 
considered as SSI because stitch abscess is considered the minimal 
inflammation and discharge limited only to the point of suture penetration (Horan 
et al., 1992). 
SSI remain as the most common Healthcare-associated infection (HCAI) 
especially in patients who underwent surgery (Dionigi et al., 2001). According to 
a surveillance done in the United States acute hospital in year 2011, SSI made 
up of 21.8% of inpatient infections (Magill et al., 2014).  
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Studies reported that prevalence rate of SSI were range between 1.8% 
and 20.3%, depends on the types of surgery (Dimick et al., 2004; Khan et al., 
2006; Emmanuel et al., 2012). Epidemiology studies reported that prevalence of 
SSI were 1.9% in United States, 0.6% in Scotland, 5-10% in Australia and Japan, 
and 12.9% in University of Malaya Medical Centre (Hughes et al., 2005; Coleman 
et al., 2010; Scottish Surveillance of Healthcare Associated Infection Programme., 
2010; Tan et al., 2010; Mu et al., 2011).  
Microorganisms responsible for the development of SSI varies. 
Staphylococcus aureus (S. aureus) was reported as one of the leading causative 
agent for SSI (A. report from the NNIS System., 2004; Magill et al., 2014). But in 
the past decade, Methicillin-resistance Staphylococcus aureus (MRSA) was 
responsible for most of the SSI and it becomes a challenge for medical 
practitioner due to emergence and spread of resistance to a wide range of 
antibiotics (Klein et al., 2007). Streptococcus sp. is the second most common 
pathogen for SSI, followed by Enterococcus sp. and Pseudomonas aeruginosa 
(Weigelt et al., 2009). 
SSI often led to substantial morbidity and mortality in some patients. 
Several studies reported that mortality rate of SSI were between 3% and 25.3% 
(Kathryn B. Kirkland et al., 1999; Awad, 2012; Horasan et al., 2013). A study done 
in Duke University Medical Center and Durham Regional Hospital had reported 
mortality rate of SSI patient with MSSA was 6.7% and MRSA was 20.7%, MRSA 
infected patients are 3.4 times at higher risk to die in 90-day post operation 
(Engemann et al., 2003). 
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 Besides that, the duration of hospital stay of SSI patient are also longer 
than patients that did not develop any complication by two to 36 days, depending 
on types of surgical intervention (Kathryn B. Kirkland et al., 1999; Dimick et al., 
2004; Broex et al., 2009; Jenks et al., 2014). Prolonged hospital stay will require 
more resources, included additional diagnostic tests, and therapeutic use of 
antibiotics. It also reduces the availability of beds for other patients as well as 
human resources. As a consequences, this not only increase the financial burden 
of patients’ family but also burden the healthcare system and economic. 
 A study done in the year 2009 has found that treating a SSI patient 
required as high as 10,523 British pound (Tanner et al.), which include extended 
hospital charges, medicine as well as additional diagnostic tests. Many factors 
can affect the postoperative outcome of the patients such as patient-related (age, 
underlying disease, tobacco use, diabetic mellitus status, obesity) and procedure-
related (method of skin preparation, selection of prophylactic antibiotics, duration 
of operation, surgeon experience) (Arabshahi and Koohpayezade, 2006; Utsumi 
et al., 2010; Hafez et al., 2012). Identification of modifiable risk factors for SSI 
helps in developing the prevention strategies on reducing SSI, especially in 
limited resources healthcare facilities. 
 SSI is a preventable surgical complication. Many SSI can be prevented if 
SSI care bundle has been applied properly. The National Institute for Health and 
Care Excellence (NICE) had published a guideline on prevention and treatment 
of SSI in year 2008 (Leaper et al., 2008). This guideline gives details of the 
methods on how to prevent SSI in pre-, intra- and postoperative phase. 
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 Most of the time, our local data consist only those who acquired the 
infection during hospitalization period, but SSI can develop within 30 days after 
surgery. Lack of close monitoring system which failed to capture the SSI cases 
from the patients that seek treatment from private clinical or other healthcare 
institutional lead to under reporting the incidence rate. Knowing the incidence is 
crucial to develop infection control policy for SSI. Furthermore, a cohort 
prospective study will enable us to do elaborate profiles of the patient who 
develop SSI and identify the problems with regards to preoperative preparation, 
during operation, post-operative wound care and co morbid illness associated 
with SSI. 
 Peacock et al. (2002) demonstrated virulent genes play a role in 
determining invasive disease of S. aureus as well as its effect was accumulative 
and increase the risk of disease. Among the S. aureus virulence genes, collagen 
adhesins (cna), polysaccharide intercellular adhesins (ica), gamma haemolysin 
(hlg), and putative adhesins (SdrE) are the most common isolated virulence gene 
in invasive isolates (Peacock et al., 2002). By studying the associated virulence 
genes in S. aureus can help in demonstrating their involvement in the occurrence 
of SSI. 
Therefore this study set up to determine the incidence and quantify the risk 
factors of SSI. This is an essential step in order to develop the preventive strategy 
to reduce the occurrence of SSI. In addition, identify the causative agent, 
especially S. aureus and MRSA strain by using molecular method is not 
necessary for treatment in SSI but can determine the evolution of the properties 
of S. aureus and MRSA as well as provides useful information for characterization 
of S. aureus and MRSA strain. 
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CHAPTER 2  
LITERATURE REVIEW 
2.1 Surgical Site Infections (SSI) 
 SSI is an infection that occurs at site of incision or any anatomical parts 
that was either opened or manipulated during surgical procedure. It can occur 
within 30 days after surgical procedure or within one year if involve implantation. 
Complication of a SSI may range from spontaneously wound pus discharge and 
inflammation to life-threatening, such as a sternal wound infection after CABG 
surgery.  
SSI may caused by contamination of an incision with microorganisms 
either from the instruments, environment or patient's own body during surgery. 
However, SSI caused by microorganisms from an outside source following 
surgery is less common. SSI can badly effect on patient’s quality of life and 
associated with considerable morbidity and extended hospital stay.  
In addition, prolonged hospital stay will require more resources, included 
additional diagnostic tests, and therapeutic use of antibiotics. As a consequences, 
this not only increase the financial burden of patients’ family but also burden the 
healthcare system and economic. Besides that, patients in primary care are 
allowed to discharge home earlier on the day or following day case as well as 
fast-track surgery are associated in increased numbers of infections. 
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2.1.1 Signs of SSI 
According to Leaper et al. (2008), the common signs and symptoms 
presence in surgical site infections are: 
1. Moderate to high grade fever (a low grade fever on the first two days is 
common due to physiological respond following surgery). 
2. Foul smelling drainage or pus from the wound. It can be bloody, greenish, 
whitish, yellowish or mixed colours. The drainage may be foamy or thick. 
3. Swelling of the wound, sometimes can feel hardening as the tissue 
underneath are inflamed. 
4. Warm feeling on the skin around the wound. 
5. Redness of the surrounding skin around the wound, sometimes may even 
feel warm. 
6. Pain or tenderness around the wound. Normally following operation, the 
pain is steadily and slowly diminished during healing process, but if the 
pain increases for no reason, probably there is an infection developing in 
the wound. 
 
The above symptoms present on the first 48-72 hours are usually normal 
physiological response following surgery due to the healing process, but if it 
becomes severe and worsen or delayed healing, then infection should be 
suspected. A more specific clinical diagnostic criteria based on signs and 
symptoms is used to define an SSI according to site of infection can be found on 
Table 2.1 (Horan et al., 1992). 
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2.1.2 Sites of SSI 
 Based on the site of infection, SSI can be classified into three categories, 
which are superficial, deep, and organ or space. Superficial SSI occurred at the 
epidermis, dermis and subcutaneous fat tissue layer; deep SSI occurred at the 
fascia and muscle under the subcutaneous fat tissue layer; and organ or space 
SSI occurred at the organ or space within the body (Figure 2.1). 
 Any infections that involve more than two layers will be classified into the 
deeper site. For example infection that involved superficial and deep layer is 
classified as deep SSI.  
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Table 2.1 Criteria for defining a SSI (Horan et al., 1992) 
 
  
Superficial lncisional SSt 
Infection occurs within 30 days after 
the operation and 
Infection involves only skin or subctJtaneous tissue 
of the incision and at least one of the following: 
1. Purulent drainage, w~h or without laboratory confirmation . from the superficial Incision. 
2.0rganlsms isolated from an aseptically obtained culture of nuld or tissue from the superficial Incision. 
3.At least one of the following signs or symptoms of infection: pain or tenderness, localized swelling, redness. or 
heat and superticial incision is deliberately opened by surgeon, unless incision is culture-negative. 
4. Diagnosis of superficial incisional SSI by the surgeon or attending physician. 
Do not repon the following conditions as SSt: 
1.Stitch abscess (minimal Inflammation and discharge confined to the poln1s of suture penetration). 
2.1nfecUon of an episiotomy or newborn circumcision site. 
3.1nfected bum wound. 
4.1ncisional SSt that el<lends into the fascial and muscle layers (see deep incisional SSI). 
Note: specific c1iteria afe used for identifying infected episiotomy and circumcision sites and burn wounds. 
Deep tncisionat SSt 
Infection occurs within 30 days after the operation if no implant is left in place or within 1 year if implant is in place 
and the inrectioo appears to be related to the operation 
and 
Infection involves deep sofi tissues (e.g .. fascial and muscle 
layers) of the incision and at least one of the foiiOINing: 
1. Purulent drainage from tile deep Incision but not from the organ/space component of the surgical s~e. 
2.A deep incision spontaneously dehisces or is deliberately opened by a surgeon \'ihen the patient has at least 
one of the following signs or symptoms: fever {>38°C), localized pain, or tendemess, unless site is cutture-
negative. 
3.An abscess or other evidence of infection involving the deep incision is found on direct examination, during 
reoperation, or by histopathologic or radiologic examination. 
4. Diagnosis of a deep lnclslonat SSt by a surgeon or attending physician. 
Notes: 
1.Report infection that involves both superticial and deep incision s~es as deep incisional SSt. 
2. Repon an organ/space SSI that drains through the incision as a deep incisional SSt. 
Organ!Space SSt 
Infection oocurs within 30 days after the operation if no implant is left in place or within 1 year if implant is in place 
and the infection appears to be related to the operation 
8tJd 
Infection involves any part of the anatomy {e.g., organs or spaces). other than the incision, which was opened or 
manipulated during an operation and at least one of the following: 
1. Purulent drainage from a drain that Is placed through a stab wound Into the organ/space. 
2.0rganlsms Isolated from an aseptically obtained culture of nuld or Ussue In the organ/space. 
3.An abscess or other evidence of infection involving the organfspace that is found on direct examination, 
during reoperation, or by histopathologic or radiologic examination. 
4. Diagnosis of an organ/space sst by a surgeon or attending physician. 
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Figure 2.1 Cross-section of abdominal wall according to the CDC classifications 
of SSI. (Adapted from Horan et al. (1992)) 
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2.1.3 Class of SSI 
Besides the classification based on to the site of infection, SSI also can be 
categorized according to the types of surgical wounds (Table 2.2).  
 
Table 2.2 The CDC criteria were used to classify and define the types of surgical 
wounds (Mangram et al., 1999). 
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2.1.4 Risk Factors for SSI 
 Development of SSI influenced by various factors, such as smoking, 
advanced age as well as procedure-related factors, including surgeon experience, 
and inappropriate antimicrobial prophylaxis. By eliminating or minimize these risk 
factors, the risk of SSI can be reduced or prevented (Savage and Anderson, 
2013). Risk factors can be divided into patient-related and procedure-related. 
Among these, some risks are modifiable while some are not (Table 2.3). 
 
Table 2.3 Risk factors that affect the outcome of surgery (Mangram et al., 1999; 
Phillips et al., 2014). 
 Patient-related risk factors Procedure-related risk factors 
Modifiable Nutritional status Length of preoperative 
hospitalization 
 Uncontrolled blood sugar level Duration of surgery 
 Smoking Preoperative skin preparation 
 Immunosuppression Preoperative hair removal 
 Alcoholism Preoperative antimicrobial 
prophylaxis 
 Colonization with 
microorganisms 
Sterilization of instruments 
 Anaemia Patient’s body temperature during 
intraoperative period 
 Co-existent infection at other 
part of the body 
Operating room ventilation 
Non-
modifiable 
Age Foreign material in the surgical 
site 
 Renal failure Surgical drains 
 Jaundice Surgeon experience 
 Malnutrition Surgeon technique 
 Ascities Length of postoperative 
hospitalization 
 Obesity  
 Cancer  
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 Modifiable risk factors such as patient’s nutritional status, blood sugar level, 
anaemia, and smoking status can be modified and eliminated. For example 
patient with hyperglycaemia can be treated and normalize the blood sugar level 
prior to operation. While non-modifiable risk factors such as age, renal failure and 
malnutrition cannot be restored to normal. 
 Although not all risk factors are modifiable, but optimizing modifiable risk 
factors before surgery can reduce the risk of SSIs (Savage and Anderson, 2013). 
However, this only applied on the elective surgery. For emergency operation, due 
to the urgency and short of time to optimize the modifiable risk factors, not all 
modifiable risk cannot be treated prior the operation, and emergency operation 
itself also as a risk factor that contribute to SSI (Neumayer et al., 2007). 
 
2.1.5 Prevention Bundles 
 SSI is a preventable surgical complication. Strictly follow the infection 
control measures during pre-, intra- as well as post-operation were able to reduce 
and prevent the occurrence of SSI. One of the prevention strategies is the 
concept of care bundles. Majority of SSIs can be prevented by implement care 
bundles (Herruzo Cabrera, 2010; Miyahara et al., 2014; Phillips et al., 2014). 
According to the NICE guideline, care bundles are divided into three phases, 
which are preoperative, intraoperative and postoperative phases (Leaper et al., 
2008). Each phase consists of several measures to minimize the risk of SSI, and 
all of this known as care bundle. 
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2.1.5.1 Preoperative Care Bundles 
 
2.1.5.1 (i) Optimize patient’s risk factors 
Risk factors such as gender, age, duration of surgery, anaemia, cigarette 
smoking, diabetes mellitus and obesity were evaluated. Their association and 
influence on occurrence of SSI was studied as well. However, risk factors such 
as gender and age are not modifiable. Therefore focusing on modifiable risk 
factors (Table 2.3) such as smoking cessation, weight reduction, diabetic control, 
reduce or stop alcoholic consumption, and coexisting infection are essential and 
they should be optimized and treated prior to any elective operation (Neumayer 
et al., 2007; Ministry of Health Malaysia., 2010). 
 
2.1.5.1 (ii) Nasal Screening for Methicillin-resistance Staphylococcus 
aureus 
 Many previous studies revealed that S. aureus was the commonest 
isolated pathogen involved in SSI, it accounts up to 46% of Methicillin-sensitive 
and Methicillin-resistance Staphylococcus aureus (MRSA) (Owens and Stoessel, 
2008; Weigelt et al., 2009; Kang et al., 2012; Takesue et al., 2012).  
Epidemiologic studies have shown that majority of SSI are originated from 
patients itself, such as endogenous flora and nasal colonization. 
 S. aureus is a pathogenic microorganism, however it colonized in human 
skin flora as transient and resident flora in 20% of normal healthy adult 
(Kluytmans et al., 1997). It commonly colonized on skin, axilla, perineal area, 
groin, and anterior nares (Friedrich et al., 2006). NICE guidelines (2008) 
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recommends nasal decolonization should only target to patients who are nasally 
colonised with MRSA instead of all S. aureus. However, a few studies have 
shown that nasal decolonization for both Methicillin-sensitive S. aureus (MSSA) 
and MRSA significantly reduce the incidence of SSI (Bode et al., 2010; Rao et al., 
2011). 
 MRSA decolonization protocol are very depends on the health care 
institutions and hospitals. Based on the latest MRSA decolonization protocol from 
Hospital USM, MRSA nasal carriage should be treated with either Mupirocin 2% 
ointment three times a daily for five days or Chlorhexidine 1% cream three times 
daily for seven days (Hospital Universiti Sains Malaysia., 2012). 
 
2.1.5.1 (iii) Antimicrobial Prophylaxis 
 Antimicrobial prophylaxis is the use of antibiotics in order to prevent the 
occurrence of infection (Wendy, 2005). Antimicrobial agent used for prophylaxis 
should be actively against and cover the most common and most likely cause of 
infection during and after the procedure (Ministry of Health Malaysia., 2010). The 
selection of antibiotics to be used as prophylaxis must ideally based on the 
antibiogram pattern of the particular institution or hospital, therefore the choice of 
antimicrobial agent would not be same in every hospital, nation and region. 
NICE guidelines recommends a single dose of intravenous antimicrobial 
prophylaxis to be given to clean surgery that involved implant or prosthetic 
placement; clean-contaminated surgery; contaminated surgery and dirty-infected 
operation within 60 minutes prior to the incision. Repeat dose should be given 
when the duration of operation is longer than the half-life of the antimicrobial 
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agent (Leaper et al., 2008; Phillips et al., 2014). Benefit and efficacy on 
antimicrobial prophylaxis is well established and a study conducted by Mazaki 
(2014) also found that there were significant reduction of incidence of SSI when 
patients were given antimicrobial prophylaxis. 
 According to the National Antibiotic Guideline (2008) published by Ministry 
of Health, Malaysia, it recommends antimicrobial prophylaxis to be given as soon 
as the patient has been stabilized after induction (Table 2.4). Continuing 
antimicrobial prophylactic until removal of surgical drain is not recommended. 
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Table 2.4 Antimicrobial prophylaxis agent recommended by Ministry of Health, 
Malaysia (Ministry of Health Malaysia., 2008). 
Type of operation Preferred 
chemoprophylaxis 
agent 
Alternative 
chemoprophylaxis 
agent 
Coronary artery 
bypass graft 
β-lactam/β-lactamase 
inhibitors, e.g. 
Amoxycillin/Clavulanate 
1.2g IV 
OR 
Ampicillin/Sulbactam 
1.5g IV 
OR 
Cefazolin 1g IV 
OR 
Cloxacillin 1g IV 
Cefuroxime 1.5g IV 
Laparoscopic 
cholecystectomy 
Cefuroxime 1.5g IV 
OR 
3rd gen. Cephalosporins, 
e.g. 
Cefoperazone 1g IV 
β-lactam/β-lactamase 
inhibitors, e.g. 
Ampicillin/Sulbactam 
1.5g IV 
OR 
Amoxycillin/Clavulanate 
1.2g IV 
Hernioplasty Cloxacillin 1g IV β-lactam/β-lactamase 
inhibitors, e.g. 
Amoxycillin/Clavulanate 
1.2g IV 
OR 
Ampicillin/Sulbactam 
1.5g IV 
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2.1.5.1 (iv) Hair Removal 
 Removal of hair during routine operation is not recommended, unless that 
area interfere the incision site (National Institute for Health and Care Excellence., 
2008). Hair removal can be done in such case, if it’s necessary, and it’s preferable 
to use electronic clippers instead of razor or shaving to reduce the injury on skin 
that can lead to colonization or infection (National Institute for Health and Care 
Excellence., 2008; Phillips et al., 2014). Infection control guideline published by 
Minister of Health, Malaysia (2010) recommend hair removal should be done just 
before operation. 
 
2.1.5.1 (v) Other preoperative measures 
 Besides that, NICE guideline also recommends patient to shower or bath 
preoperatively, wear antiseptic impregnated clothes and to avoid routine 
mechanical bowel preparation to reduce SSI (Leaper et al., 2008; Savage and 
Anderson, 2013). 
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2.1.5.2 Intraoperative Care Bundles 
2.1.5.2 (i) Operating Room Environment 
 Operating room must be clean from any soil or contamination of any body 
fluids, such as blood. Air entered operating room must be filtered and maintained 
at least 15 to 20 air changes hourly. Operating room must also under positive 
pressure, temperature optimized at around 21°C and humidity should be 
maintained around 40-60% (Owens and Stoessel, 2008; Ministry of Health 
Malaysia., 2010; Phillips et al., 2014). 
 
2.1.5.2 (ii) Skin Preparation 
 Skin should be sterilized just before incision by using antiseptics. Common 
antiseptics used for operation is either povidone-iodine or chlorhexidine alcohol 
aqueous. Studies compared the efficacy of povidone-iodine or chlorhexidine 
alcohol to sterilize the skin shown that chlorhexidine alcohol offered significant 
protection and more advance than povidone-iodine (Macias et al.; Darouiche et 
al., 2010; Noorani et al., 2010; Banjong et al., 2011). 
 
2.1.5.2 (iii) Maintaining Patient’s Body Temperature and Homeostasis 
 Maintaining patient’s body temperature, oxygenation, perfusion and 
homeostasis during intraoperative period are important to reduce the chances of 
SSI. Patient who was hypothermia during intraoperative period required longer 
time in wound healing and increase occurrence of SSI (Kurz et al., 1996). Studies 
also found that hypothermia patients stayed longer during postoperative 
hospitalization period (Kurz et al., 1996; Harper et al., 2003). 
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2.1.5.2 (iv) Other intraoperative measures 
 Surgeons, anaesthesiologists, nurses as well as other operating team 
members that involves in operation must strictly follow WHO (2009) Hand 
Hygiene Guideline when decontaminate their hands. Operating team members 
must also wear sterile gowns, gloves, facemasks, and caps during the operation 
to minimize the SSI due to transmission of potential pathogens (Leaper et al., 
2008; Owens and Stoessel, 2008). Besides that, surgeon experience and skill 
also greatly affect the outcome (Phillips et al., 2014). 
 
2.1.5.3 Postoperative Care Bundles 
2.1.5.3 (i) Wound Care 
 Unless dressing soaked, otherwise sterilize dressing on primarily closed 
wound should be protected 24 to 48 hours postoperatively. If inspection, changing, 
or removing of dressing are necessary during first 48 hours, use an aseptic 
technique and strictly compiled to WHO Hand Hygiene Guideline (Leaper et al., 
2008; Owens and Stoessel, 2008; World Health Organization., 2009; Ministry of 
Health Malaysia., 2010; Phillips et al., 2014). 
 
2.1.5.4 Treatment of SSI 
 Treatment of SSI is basically based on the site of infection. Once SSI was 
diagnosed by surgeon or physician, early empiric antimicrobial agent is important 
to eliminate the pathogen. For superficial SSI and pus discharge, wound 
cleansing is the first step to remove the pus and disinfect the surrounding tissue. 
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 In deep SSI, the pus may locate beneath the superficial tissue. In such 
condition, drainage of pus and fluid from the infected site is adequate while in 
severe case, debridement of the wound and an affected tissue is necessary. 
Occasionally, patient is required to be hospitalized and re-operate the wound. 
 Organ or space SSIs are often diagnosed by signs of infection and 
instrumental examination. Drainage of pus are done under the guidance of 
ultrasonography or computed tomography examination. If it’s not possible, re-
operate would be the only choice of treatment. 
 Debrided tissue, aspirated pus or pus swab should be quickly transport to 
laboratory for identification of pathogenic microorganism as well as antimicrobial 
sensitivity test to find out the most suitable antimicrobial agent. 
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2.2 Staphylococcus aureus 
Staphylococcus was first identified by a Scottish surgeon, Sir Alexander 
Ogston, in pus from a surgical abscess in a knee joint in Aberdeen, United 
Kingdom in year 1880. He proposed the name ‘Staphylococci’ based on its shape 
and morphology (Humphreys, 2012). Staphylococci are resistant to high salt 
concentration as well as dry conditions, therefore it can survive for long periods 
in the environment such as the skin and upper respiratory tract of human and 
animals. 
Staphylococcus aureus (S. aureus) is the major pathogen in the genius 
Staphylococcus, due to its ability to infect human and animals. It is differentiated 
from other species by its ability to clot blood plasma via the action of enzyme 
coagulase (Humphreys, 2012). 
 
List below is the hierarchy taxonomic for S. aureus (UniProt., 2014). 
Domain: Bacteria; 
Phylum: Firmicutes; 
Class:  Bacilli; 
Order:  Bacillales; 
Family: Staphylococcaceae; 
Genus: Staphylococcus; 
Species: Staphylococcus aureus 
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 S. aureus are grouped under genus Staphylococcus within family 
Staphylococcaceae. The microorganism is Gram-positive, round shape, 
arranged in grape-like cluster, about 1µm in diameter, non-sporing, non-motile, 
usually non-capsulated, produce enzyme coagulase, and ferment mannitol 
(Chapman, 1945; Humphreys, 2012). Therefore it produces positive reaction in 
mannitol salt agar and changes the colour from red/pink to yellow. This 
microorganism can grow on most types of media, including Mueller Hinton agar, 
blood agar, DNase agar, Tryptic Soy Agar, and Mannitol Salt agar (MSA). Its 
colonies are circular, smooth and shiny surface, and often pigmented. 
 It differs from other microorganism by mean of the characteristic 
appearance on Mannitol Salt agar and DNase agar. On Mannitol Salt agar, its 
yellow appearance due to the ability to ferment mannitol while on DNase agar, a 
clear zone surround the colonies can be seen when added a few drop of 
hydrochloride acid. S. aureus was then confirmed by tube coagulase test to differ 
from other coagulase-negative Staphylococci. 
 
2.2.1 Pathogenicity 
 S. aureus is present in the nose of 21.5 - 30% of healthy individual and 
may be found on the skin as well (Fishbain et al., 2003; Davis et al., 2004; Alex, 
2007; Humphreys, 2012).  
 It is an opportunistic pathogen that can cause a numerous diseases, from 
minor skin infections to life threatening diseases, such as impetigo, scalded skin 
syndrome, abscesses, osteomyelitis, pneumonia, meningitis, endocarditis, toxic 
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shock syndrome (TSS), sepsis as well as surgical site infection. It also one of the 
major causative organisms in surgical site infection. 
 Our body consists of three defence mechanism to protect us from S. 
aureus invasion. Primary and the most frontier barrier consists of our skin layer, 
and physiological factors; secondary barrier is our cellular factors and 
inflammatory response, which consist of phagocytes, neutrophils, basophils, 
interleukin and other inflammatory markers; tertiary which is the final barrier 
comprises active immune response provided by lymphocytes, such as 
immunoglobulin (Hattie, 2009). 
 By the help of virulent factors, S. aureus can invade and against our 
defence barrier and cause infections. 
 
2.2.2 Virulent factors 
 S. aureus contain numbers of cell-associated and extracellular factors to 
assist it to overcome the human defend mechanism, and to colonized, invade as 
well as survive in the human body (Table 2.5). Although not all the role of every 
factors are well studied, but it’s likely that they are responsible for enabling the S. 
aureus to bind and to resist and survive from the intracellular killing by phagocytes 
and bactericidal activities from humoral factors (Humphreys, 2012). 
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Table 2.5 List of some virulent factors of S. aureus (Peacock et al., 2002; Mark 
et al., 2009; Humphreys, 2012). 
Virulent gene Function 
Adhesins  
FnbA & FnbB Adhesin for fibronectin 
ClfA, ClfB & Efb Adhesins for fibrinogen 
cna Adhesin for collagen 
Protein A Binds Fc domain of immunoglobulin and von Willibrand 
factor 
SdrC, SdrD & SdrE putative adhesins 
Bbp Adhesin for bone sialoprotein 
EbpS Adhesin for elastin 
Map/Eap Major histocompatibility complex class II analogue 
protein 
Toxins  
Toxic Shock Syndrome 
Toxin 1. (TSST-1) 
Exotoxin with superantigen activity 
Enterotoxins A, B, C, D, E, 
G, H, I & J 
Exotoxins with superantigen activity 
Exfoliative toxins A & B Exotoxins with superantigen activity 
Alpha-toxin Cytolytic pore-forming toxin 
Beta-toxin Sphingomyelinase 
Delta-toxin Cytolytic toxin 
Panton-Valentine 
leukocidin (PVL) 
Bicomponent leukocidin 
Gamma-toxin Bicomponent leukocidin 
Others  
ica locus Biofilm formation 
Coagulase Binds prothrombin, activating conversion of fibrinogen 
to fibrin 
V8 protease Serine protease 
agr subgroup Global regulator 
Lipase Degrades lipid 
Staphylokinase Degrades fibrin 
Deoxyribonuclease Degrades DNA 
Epidermolytic toxins Cause blistering of skin 
Cell wall polymers  
Peptidoglycan Inhibits inflammatory response; endotoxin-like activity 
Teichoic acid Phage adsorption; reservoir of bound divalent cations 
 
